Curis to Present at Techvest Conference 2002
Tuesday October 22, 8:04 am ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 22, 2002--Curis, Inc. (NASDAQ-CRIS) announced today that Christopher U. Missling, PhD, Chief Financial Officer, will present at Techvest's 4th Annual Healthcare Conference on October 24th, 2002, at 12:05 p.m. Dr. Missling will give a corporate overview and update of Curis' therapeutic development and partnering programs, focusing on its proprietary signaling pathway technologies. He will also elaborate on recent announcements, including additions to the Curis management team and a transaction to strengthen the company's balance sheet and further their partnering focus.
Dr. Missling will join conference presenters and representatives from an estimated 140 leading biotechnology and medical device companies from around the world for Techvest's conference, from October 22-24, 2002. Techvest, LLC is a leading investment research, consulting and investment banking firm specializing in the healthcare sector.
About Curis, Inc.
Curis, Inc. is generating therapies that regulate the pathways used by the body to maintain and restore health. The company focuses on signaling pathways that govern the proliferation and differentiation of cells. These same pathways control maintenance, repair, and regeneration of tissues and organs from infancy through old age. This approach has created an approved product for bone regeneration and enables Curis to build a portfolio of product candidates in neurology, kidney disease, and cancer. For more information, please visit the Curis web site at www.curis.com.
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements address a variety of subjects, including, for example, strategic collaboration efforts, product development efforts and prospective returns. Statements in this press release that state Curis' or management's intentions, plans, expectations or predictions of future events are forward-looking statements. The matters discussed in this press release also involve risks and uncertainties that may cause Curis' actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. The following important factors and uncertainties, among others, could cause actual results to differ materially from those described in these forward-looking statements: Curis' need for partnerships to move forward its cell therapy programs, the early stage of product development of Curis' retained programs, uncertainties related to clinical trials, uncertainties related to Curis' ability to raise additional capital, changes in or an inability to execute Curis' realigned business strategy and other risk factors described from time to time in Curis' periodic reports and registration statements filed with the Securities and Exchange Commission, including, without limitation, Curis' Annual Report on Form 10-K for the year ended December 31, 2001 filed on March 29, 2002. Curis cannot guarantee any future results, levels of activity, performance, or achievements. Moreover, neither Curis nor anyone else assumes responsibility for the accuracy and completeness of any forward-looking statements. Curis undertakes no obligation to update any of the forward-looking statements after the date of this press release.
--------------------------------------------------------------------------------
Contact:
Curis, Inc.
Henry W. McCusker, 617/503-6641
or
Noonan Russo Presence
Melissa Wainberg, 212/845-4262 (media)
--------------------------------------------------------------------------------
Source: Curis, Inc. |
